South Africa will put on hold the use of AstraZeneca’s Covid-19 shot in its vaccination programme, after data showed it gave minimal protection against mild-to-moderate infection caused by the country’s dominant coronavirus variant.
Health Minister Zweli Mkhize said on Sunday that the government would await advice from scientists on how best to proceed, after a trial showed the AstraZeneca vaccine did not significantly reduce the risk of mild or moderate Covid-19 from the 501Y.V2 variant that caused a second wave of infections starting late last year.
Prior to widespread circulation of the more contagious variant, the vaccine was showing efficacy of around 75 per cent, researchers said.
In a later analysis based mostly on infections by the new variant, there was only a 22 per cent lower risk of developing mild-to-moderate Covid-19 versus those given a placebo.
Although researchers said the figure was not statistically significant, due to trial design, it is well below the benchmark of at least 50 per cent regulators have set for vaccines to be considered effective against the virus.
Prior to widespread circulation of the more contagious variant, the vaccine was showing efficacy of around 75 per cent, researchers said.
In a later analysis based mostly on infections by the new variant, there was only a 22 per cent lower risk of developing mild-to-moderate Covid-19 versus those given a placebo.
The study did not assess whether the vaccine helped prevent severe Covid-19 because it involved mostly relatively young adults not considered to be at high risk for serious illness.
AstraZeneca said on Saturday that it believed its vaccine could protect against severe disease and that it had already started adapting it against the 501Y.V2 variant.
Still, Professor Shabir Madhi, lead investigator on the AstraZeneca trial in South Africa, said data on the vaccine was a reality check and that it was time to “recalibrate our expectations of Covid-19 vaccines”.
South Africa hopes to vaccinate 40 million people, or two-thirds of the population, to achieve some level of herd immunity but is yet to administer a single shot.
